These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11228339)

  • 21. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
    Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
    Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
    Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
    Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
    Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
    Lee FM; Chan AK; Lau KK; Chan HH
    Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H
    Thromb Res; 1982 Apr; 26(1):21-9. PubMed ID: 6980497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M; Cvirn G; Gallistl S; Muntean W
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
    Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
    Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
    J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
    Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
    Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
    Boström SL; Hansson GF; Kjaer M; Sarich TC
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):457-62. PubMed ID: 12851531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
    Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
    Barthels M
    Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.
    Turecek PL; Gritsch H; Richter G; Auer W; Pichler L; Schwarz HP
    Thromb Haemost; 1997 Mar; 77(3):591-9. PubMed ID: 9066015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.